Skip to Content

Tema Oncology ETF CANC

Medalist Rating as of | See Tema Global Investment Hub

Morningstar’s Analysis CANC

Will CANC outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

The combination of a middling Process Pillar rating and a Below Average People Pillar rating limit Tema Oncology ETF to a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the second-lowest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings CANC

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 38.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Regeneron Pharmaceuticals Inc

5.56 1.0 Mil
Healthcare

Merck & Co Inc

5.33 992,453
Healthcare

Daiichi Sankyo Co Ltd

4.18 777,204
Healthcare

AstraZeneca PLC

3.88 721,571
Healthcare

Novartis AG Registered Shares

3.55 660,382
Healthcare

Amgen Inc

3.24 602,402
Healthcare

Revolution Medicines Inc Ordinary Shares

3.21 598,130
Healthcare

Illumina Inc

3.08 573,577
Healthcare

Blueprint Medicines Corp

3.00 557,296
Healthcare

argenx SE ADR

2.98 555,144
Healthcare